| scholarly article | Q13442814 |
| P356 | DOI | 10.1310/MUQC-QXBC-8118-BPM5 |
| P698 | PubMed publication ID | 14583845 |
| P50 | author | Ellen Wright Clayton | Q16902110 |
| Douglas Richman | Q5301927 | ||
| Michael Saag | Q6834090 | ||
| Jonathan L Haines | Q73570557 | ||
| Daniel Kuritzkes | Q88453812 | ||
| P2093 | author name string | David W Haas | |
| Janet Nicotera | |||
| Alastair J J Wood | |||
| Jody Lawrence | |||
| Janet Andersen | |||
| Grant R Wilkinson | |||
| Adult AIDS Clinical Trials Group | |||
| Ann Marshak | |||
| Cara Sutcliffe | |||
| Jeffrey Gustavson | |||
| Jo Anne Bennett | |||
| Kristine Coughlin | |||
| Laura F Mahon | |||
| Margaret A Matula | |||
| Rolf Christensen | |||
| Sue Siminski | |||
| P2860 | cites work | The Sequence of the Human Genome | Q22065842 |
| A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms | Q28203288 | ||
| Accessing genetic variation: genotyping single nucleotide polymorphisms | Q28208864 | ||
| Genetic variations in HLA-B region and hypersensitivity reactions to abacavir | Q28214097 | ||
| Prognosis in HIV-1 infection predicted by the quantity of virus in plasma | Q29619980 | ||
| The genetics of dilated cardiomyopathy--emerging clues to the puzzle | Q33368281 | ||
| Principles, organization, and operation of a DNA bank for clinical trials: a Department of Veterans Affairs cooperative study | Q33445084 | ||
| Pharmacogenomics: translating functional genomics into rational therapeutics | Q33751829 | ||
| Pharmacogenetics and the practice of medicine | Q33906823 | ||
| Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review | Q34102026 | ||
| Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir | Q34117815 | ||
| Molecular basis of ethnic differences in drug disposition and response | Q34192804 | ||
| Mitochondrial toxicity and HIV therapy | Q34279271 | ||
| Informed consent for genetic research on stored tissue samples | Q34290380 | ||
| Pharmacogenomics: the inherited basis for interindividual differences in drug response | Q34433440 | ||
| Ethical reflections on pharmacogenetics and DNA banking in a cohort of HIV-infected patients | Q35016337 | ||
| Genetic associations in large versus small studies: an empirical assessment | Q35070873 | ||
| Genetic epidemiology and the future of disease prevention and public health | Q40910787 | ||
| Ethical issues of genetic testing and their implications in epidemiologic studies | Q41557225 | ||
| Impact of the Human Genome Project on epidemiologic research | Q41635609 | ||
| Genetic epidemiology of psychiatric disorders | Q41635716 | ||
| Ethical and legal issues in genetic epidemiology | Q41635728 | ||
| The CCR5Delta32 allele slows disease progression of human immunodeficiency virus-1-infected children receiving antiretroviral treatment | Q41750967 | ||
| Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study | Q43865209 | ||
| Individualising HIV treatment--pharmacogenetics and immunogenetics | Q43913157 | ||
| Individual, family, and societal dimensions of genetic discrimination: a case study analysis | Q45304382 | ||
| Genomics research and human subjects | Q48003793 | ||
| Genetic discrimination: perspectives of consumers. | Q53614686 | ||
| Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy | Q54968987 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 287-300 | |
| P577 | publication date | 2003-09-01 | |
| P1433 | published in | HIV Clinical Trials | Q15756361 |
| P1476 | title | A multi-investigator/institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128. | |
| P478 | volume | 4 |
| Q37246041 | AIDS clinical trials group longitudinal linked randomized trials (ALLRT): rationale, design, and baseline characteristics |
| Q30386701 | Adaptive interactions between HLA and HIV-1: highly divergent selection imposed by HLA class I molecules with common supertype motifs. |
| Q25256933 | Antiretroviral therapy and dyslipidaemia: unlocking the code |
| Q88920008 | Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events |
| Q36414604 | Correlates of protective cellular immunity revealed by analysis of population-level immune escape pathways in HIV-1. |
| Q36701911 | Discordant associations between SLCO1B1 521T→C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146. |
| Q42583334 | Effect of HIV-1 infection on human DNA yield from saliva |
| Q34372631 | European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142 |
| Q36592753 | Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agents |
| Q35071940 | Genome-Wide Association Study of Human Immunodeficiency Virus (HIV)-1 Coreceptor Usage in Treatment-Naive Patients from An AIDS Clinical Trials Group Study |
| Q36734592 | Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants |
| Q35288691 | Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols |
| Q33760652 | Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202. |
| Q35908584 | Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202 |
| Q36094640 | Genomics meets HIV-1 |
| Q37282509 | HIV escape mutations occur preferentially at HLA-binding sites of CD8 T-cell epitopes. |
| Q33494829 | HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins |
| Q36445636 | Human genetic variability and HIV treatment response |
| Q35073490 | Human immunodeficiency virus therapeutics and pharmacogenomics |
| Q36509812 | Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202 |
| Q36984267 | Impact of pre-adapted HIV transmission. |
| Q37200459 | Influence of HLA-C expression level on HIV control |
| Q35476308 | Mitochondrial genomics and CD4 T-cell count recovery after antiretroviral therapy initiation in AIDS clinical trials group study 384 |
| Q37251569 | Pharmacogenetics of nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathy |
| Q46878731 | Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study |
| Q35846143 | Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa |
| Q37419542 | Pharmacogenomics of CYP3A: considerations for HIV treatment |
| Q41995975 | Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants. |
| Q35837813 | Screening for UGT1A1 Genotype in Study A5257 Would Have Markedly Reduced Premature Discontinuation of Atazanavir for Hyperbilirubinemia |
| Q33909996 | Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes |
| Q34411977 | T cell activation markers and African mitochondrial DNA haplogroups among non-Hispanic black participants in AIDS clinical trials group study 384. |
| Q80761703 | The mitochondrial pharmacogenomics of haplogroup T: MTND2*LHON4917G and antiretroviral therapy-associated peripheral neuropathy |
| Q37174248 | The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis |
| Q35244904 | Translation of HLA-HIV associations to the cellular level: HIV adapts to inflate CD8 T cell responses against Nef and HLA-adapted variant epitopes |
| Q34982530 | Use of biological knowledge to inform the analysis of gene-gene interactions involved in modulating virologic failure with efavirenz-containing treatment regimens in ART-naïve ACTG clinical trials participants. |
Search more.